|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang H, Ji X, Liu X, Yao R, Chi J, Liu S,
Wang Y, Cao W and Zhou Q: Lentivirus-mediated inhibition of USP39
suppresses the growth of breast cancer cells in vitro. Oncol Rep.
30:2871–2877. 2013.PubMed/NCBI
|
|
3
|
SEER Stat Fact Sheets. NCI2014.
|
|
4
|
Pinnix CC, Smith GL, Milgrom S, Osborne
EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, et al:
Predictors of radiation pneumonitis in patients receiving intensity
modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.
Int J Radiat Oncol Biol Phys. 92:175–182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pulte D, Jansen L and Brenner H: Survival
disparities by insurance type for patients aged 15–64 years with
non-Hodgkin lymphoma. Oncologist. 20:554–561. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rossi C, Jégu J, Mounier M, Dandoit M,
Colonna M, Daubisse-Marliac L, Trétarre B, Ganry O, Guizard AV,
Bara S, et al: Risk assessment of second primary cancer according
to histological subtype of non-Hodgkin lymphoma. Leuk Lymphoma.
56:2876–2882. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hochberg J, El-Mallawany NK and Abla O:
Adolescent and young adult non-Hodgkin lymphoma. Br J Haematol.
173:637–650. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
El-Mallawany NK and Cairo MS: Advances in
the diagnosis and treatment of childhood and adolescent B-cell
non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 13:113–123.
2015.PubMed/NCBI
|
|
9
|
Matsuki E and Younes A: Checkpoint
inhibitors and other immune therapies for Hodgkin and non-Hodgkin
lymphoma. Curr Treat Options Oncol. 17:312016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Frotscher M: Cajal-Retzius cells, Reelin,
and the formation of layers. Curr Opin Neurobiol. 8:570–575. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Groen JL, Ritz K, Jalalzadeh H, van der
Salm SM, Jongejan A, Mook OR, Haagmans MA, Zwinderman AH,
Motazacker MM, Hennekam RC, et al: RELN rare variants in
myoclonus-dystonia. Mov Disord. 30:415–419. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sommen M, van Camp G, Liktor B, Csomor P,
Fransen E, Sziklai I, Schrauwen I and Karosi T: Genetic association
analysis in a clinically and histologically confirmed otosclerosis
population confirms association with the TGFB1 gene but suggests an
association of the RELN gene with a clinically indistinguishable
otosclerosis-like phenotype. Otol Neurotol. 35:1058–1064. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tissir F and Goffinet AM: Reelin and brain
development. Nat Rev Neurosci. 4:496–505. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sato N, Fukushima N, Chang R, Matsubayashi
H and Goggins M: Differential and epigenetic gene expression
profiling identifies frequent disruption of the RELN pathway in
pancreatic cancers. Gastroenterology. 130:548–565. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wetmore C, Eberhart DE and Curran T: The
normal patched allele is expressed in medulloblastomas from mice
with heterozygous germ-line mutation of patched. Cancer Res.
60:2239–2246. 2000.PubMed/NCBI
|
|
16
|
Wang Q, Lu J, Yang C, Wang X, Cheng L, Hu
G, Sun Y, Zhang X, Wu M and Liu Z: CASK and its target gene Reelin
were co-upregulated in human esophageal carcinoma. Cancer Lett.
179:71–77. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Perrone G, Vincenzi B, Zagami M, Santini
D, Panteri R, Flammia G, Verzì A, Lepanto D, Morini S, Russo A, et
al: Reelin expression in human prostate cancer: a marker of tumor
aggressiveness based on correlation with grade. Mod Pathol.
20:344–351. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stein T, Cosimo E, Yu X, Smith PR, Simon
R, Cottrell L, Pringle MA, Bell AK, Lattanzio L, Sauter G, et al:
Loss of reelin expression in breast cancer is epigenetically
controlled and associated with poor prognosis. Am J Pathol.
177:232–2333. 2010. View Article : Google Scholar
|
|
19
|
Dohi O, Takada H, Wakabayashi N, Yasui K,
Sakakura C, Mitsufuji S, Naito Y, Taniwaki M and Yoshikawa T:
Epigenetic silencing of RELN in gastric cancer. Int J Oncol.
36:85–92. 2010.PubMed/NCBI
|
|
20
|
Neumann M, Vosberg S, Schlee C, Heesch S,
Schwartz S, Gökbuget N, Hoelzer D, Graf A, Krebs S, Bartram I, et
al: Mutational spectrum of adult T-ALL. Oncotarget. 6:2754–2766.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kaur IP, Kaur T, Bhardwaj R, Deol PK,
Kakkar V, Vaiphei K and Sanyal SN: Sesamol induces apoptosis by
altering expression of bcl-2 and bax proteins and modifies skin
tumor development in Balb/c mice. Anticancer Agents Med Chem.
16:12016.
|
|
22
|
Ugland H, Boquest AC, Naderi S, Collas P
and Blomhoff HK: cAMP-mediated induction of cyclin E sensitizes
growth-arrested adipose stem cells to DNA damage-induced apoptosis.
Mol Biol Cell. 19:5082–5092. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bleyer A, Viny A and Barr R: Cancer in 15-
to 29-year-olds by primary site. Oncologist. 11:590–601. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin L, Wang P, Liu X, Zhao D, Zhang Y, Hao
J, Liang X, Huang X, Lu J and Ge Q: Epigenetic regulation of reelin
expression in multiple myeloma. Hematol Oncol. Jun
1–2016.https://doi.org/10.1002/hon.2311 View Article : Google Scholar
|
|
25
|
Yuan Y, Chen H, Ma G, Cao X and Liu Z:
Reelin is involved in transforming growth factor-β1-induced cell
migration in esophageal carcinoma cells. PLoS One. 7:e318022012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liberman AC, Refojo D, Antunica-Noguerol
M, Holsboer F and Arzt E: Underlying mechanisms of cAMP- and
glucocorticoid-mediated inhibition of FasL expression in
activation-induced cell death. Mol Immunol. 50:220–235. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sen R: Control of B lymphocyte apoptosis
by the transcription factor NF-kappaB. Immunity. 25:871–883. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takahashi N, Tetsuka T, Uranishi H and
Okamoto T: Inhibition of the NF-kappaB transcriptional activity by
protein kinase A. Eur J Biochem/FEBS. 269:4559–4565. 2002.
View Article : Google Scholar
|
|
29
|
Parry GC and Mackman N: Role of cyclic AMP
response element-binding protein in cyclic AMP inhibition of
NF-kappaB-mediated transcription. J Immunol. 159:5450–5456.
1997.PubMed/NCBI
|
|
30
|
Lømo J, Blomhoff HK, Beiske K, Stokke T
and Smeland EB: TGF-beta 1 and cyclic AMP promote apoptosis in
resting human B lymphocytes. J Immunol. 154:1634–1643.
1995.PubMed/NCBI
|
|
31
|
Ivanov VN, Lee RK, Podack ER and Malek TR:
Regulation of Fas-dependent activation-induced T cell apoptosis by
cAMP signaling: A potential role for transcription factor NF-kappa
B. Oncogene. 14:2455–2464. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang L, Zambon AC, Vranizan K, Pothula K,
Conklin BR and Insel PA: Gene expression signatures of cAMP/protein
kinase A (PKA)-promoted, mitochondrial-dependent apoptosis.
Comparative analysis of wild-type and cAMP-deathless S49 lymphoma
cells. J Biol Chem. 283:4304–4313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zambon AC, Zhang L, Minovitsky S, Kanter
JR, Prabhakar S, Salomonis N, Vranizan K, Dubchak I, Conklin BR and
Insel PA: Gene expression patterns define key transcriptional
events in cell-cycle regulation by cAMP and protein kinase A. Proc
Natl Acad Sci USA. 102:pp. 8561–8566. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moore AR and Willoughby DA: The role of
cAMP regulation in controlling inflammation. Clin Exp Immunol.
101:387–389. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ishida M, Mitsui T, Yamakawa K, Sugiyama
N, Takahashi W, Shimura H, Endo T, Kobayashi T and Arita J:
Involvement of cAMP response element-binding protein in the
regulation of cell proliferation and the prolactin promoter of
lactotrophs in primary culture. Am J Physiol Endocrinol Metab.
293:E1529–E1537. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Snijdewint FG, Kaliński P, Wierenga EA,
Bos JD and Kapsenberg ML: Prostaglandin E2 differentially modulates
cytokine secretion profiles of human T helper lymphocytes. J
Immunol. 150:5321–5329. 1993.PubMed/NCBI
|
|
37
|
Hilkens CM, Snijders A, Snijdewint FG,
Wierenga EA and Kapsenberg ML: Modulation of T-cell cytokine
secretion by accessory cell-derived products. Eur Respir J (Suppl).
22:90s–94s. 1996.PubMed/NCBI
|
|
38
|
Aandahl EM, Aukrust P, Skålhegg BS, Müller
F, Frøland SS, Hansson V and Taskén K: Protein kinase A type I
antagonist restores immune responses of T cells from HIV-infected
patients. FASEB J. 12:855–862. 1998.PubMed/NCBI
|
|
39
|
Platzer C, Fritsch E, Elsner T, Lehmann
MH, Volk HD and Prösch S: Cyclic adenosine monophosphate-responsive
elements are involved in the transcriptional activation of the
human IL-10 gene in monocytic cells. Eur J Immunol. 29:3098–3104.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Platzer C, Meisel C, Vogt K, Platzer M and
Volk HD: Up-regulation of monocytic IL-10 by tumor necrosis
factor-alpha and cAMP elevating drugs. Int Immunol. 7:517–523.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gaiano N and Fishell G: The role of notch
in promoting glial and neural stem cell fates. Annu Rev Neurosci.
25:471–490. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brai E, Marathe S, Astori S, Fredj NB,
Perry E, Lamy C, Scotti A and Alberi L: Notch1 regulates
hippocampal plasticity through interaction with the Reelin pathway,
glutamatergic transmission and CREB signaling. Front Cell Neurosci.
9:4472015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rogers JT, Rusiana I, Trotter J, Zhao L,
Donaldson E, Pak DT, Babus LW, Peters M, Banko JL, Chavis P, et al:
Reelin supplementation enhances cognitive ability, synaptic
plasticity, and dendritic spine density. Learn Mem. 18:558–564.
2011. View Article : Google Scholar : PubMed/NCBI
|
